TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15232326

Group type: EXPERIMENTAL
Intervention: Olanzapine (OLZ) 5 to 20 mg/d
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Olanzapine/fluoxetine combination (OFC) 5 to 20 mg/d olanzapine + 20 to 80 mg/d fluoxetine
Number of subjects: 249

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 249
Study: 11547961

Group type: EXPERIMENTAL
Intervention: Steroid-containing drug delivery system (DDS)
Number of subjects: 63

Group type: COMPARATOR
Intervention: 0.1% dexamethasone eyedrops (control)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Topical chloramphenicol eyedrops
Number of subjects: 63
Study: 9258878

Group type: EXPERIMENTAL
Intervention: nRBC count in PROM
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: nRBC count in PTL
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: nRBC count in preeclampsia
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: nRBC count in well‐grown, nonacidotic, nondepressed preterm infants
Number of subjects: 465
Study: 8335134

Group type: EXPERIMENTAL
Intervention: 20 mg of zinc supplementation during pregnancy
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Zinc taste test
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 494
Study: 6643334

Group type: EXPERIMENTAL
Intervention: Amikacin
Number of subjects: 135

Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 135
Study: 30209161

Group type: EXPERIMENTAL
Intervention: TP53 inactivation
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Tumor burden estimates (CTC counts, ctDNA fraction, and visceral metastases)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Prognostic groups based on TP53 status
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Validation in independent mCRPC cohort (n = 202)
Number of subjects: 168
Study: 28406132

Group type: EXPERIMENTAL
Intervention: Tolterodine
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 25656058

Group type: EXPERIMENTAL
Intervention: Liraglutide once daily
Number of subjects: 9340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9340
Study: 24797300

Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) with chemotherapy (idarubicin, cytarabine, and all-trans retinoic acid)
Number of subjects: 186

Group type: COMPARATOR
Intervention: STANDARD (idarubicin, cytarabine, and all-trans retinoic acid without VPA)
Number of subjects: 186
Study: 23034121

Group type: EXPERIMENTAL
Intervention: Percutaneous balloon angioplasty (PTA)
Number of subjects: 679

Group type: COMPARATOR
Intervention: Sham PTA
Number of subjects: 679

Group type: EXPERIMENTAL
Intervention: PTA
Number of subjects: 679
Study: 19100331

Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Withdrawal from cigarette smoking for 12 h (SM)
Number of subjects: 20
Study: 17587852

Group type: EXPERIMENTAL
Intervention: Shoe fitting guidance and wearing shoes with custom-made insoles (CMI) for 1 month
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group had a 30-min lecture on better ways of choosing shoes
Number of subjects: 79
Study: 16845131

Group type: EXPERIMENTAL
Intervention: L-IVRA group (lidocaine 0.5% with lornoxicam)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (i.v. saline and IVRA with lidocaine 0.5%)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: L-IV group (intravenous lornoxicam and IVRA lidocaine 0.5%)
Number of subjects: 45
Study: 12720593

Group type: EXPERIMENTAL
Intervention: Nutritional supplements
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57

Group type: COMPARATOR
Intervention: Memory training
Number of subjects: 57
Study: 10582397

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate (CIAN)
Number of subjects: 74
Study: 9156928

Group type: EXPERIMENTAL
Intervention: Grass pollen extracts (Allergovit, Allergopharma, Germany) for 7 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study: 1928686

Group type: EXPERIMENTAL
Intervention: Propofol (1.6 mg/kg to 2.6 mg/kg in 0.2 mg/kg increments)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Propofol mixed with lignocaine (0.5 mg/ml)
Number of subjects: 216
Study: 6409239

Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 96

Group type: COMPARATOR
Intervention: Non-operative treatment
Number of subjects: 96
Study: 31560736

Group type: EXPERIMENTAL
Intervention: 0.1% capsaicin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 5% EMLA
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vaseline (placebo)
Number of subjects: 20
Study: 30932955

Group type: EXPERIMENTAL
Intervention: MGN1703 (TLR9 agonist); 60 mg × 2 weekly for 24 weeks
Number of subjects: 12
Study: 28700718

Group type: EXPERIMENTAL
Intervention: Reduction of diabetes-related distress (PAID scale)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Continuous measures of diabetes distress
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Higher age
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 181
Study: 26033508

Group type: EXPERIMENTAL
Intervention: BFST‐D via Skype (Internet videoconferencing)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BFST‐D via Clinic (face to face)
Number of subjects: 0
Study: 23138399

Group type: EXPERIMENTAL
Intervention: Milrinone (MR; 0.5‐1 μg/kg/min)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Levosimendan (LEVO; 0.1‐0.2 μg/kg/min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Milrinone (MR)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Levosimendan (LEVO)
Number of subjects: 20
Study: 21443311

Group type: EXPERIMENTAL
Intervention: Drink refusal skills training module
Number of subjects: 776

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 776
Study: 19637474

Group type: EXPERIMENTAL
Intervention: Extraction of four first premolars
Number of subjects: 30

Group type: COMPARATOR
Intervention: Extraction of two maxillary first premolars and two mandibular first molars
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Extraction of two maxillary first premolars and two mandibular first molars with additional micro-implants for orthodontic anchorage
Number of subjects: 30
Study: 16843643

Group type: EXPERIMENTAL
Intervention: Fexofenadine and emollient treatment (Group 1) for 1 week
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fexofenadine and steroid treatment (Group 2) for 1 week
Number of subjects: 20
Study: 14668584

Group type: EXPERIMENTAL
Intervention: Radio-frequency energy delivery via Secca® system
Number of subjects: 50
Study: 10692000

Group type: EXPERIMENTAL
Intervention: Minimally invasive video‐assisted thoracic surgery (VATS)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional thoracic surgery
Number of subjects: 41
Study: 9172724

Group type: EXPERIMENTAL
Intervention: Premixing propofol with lidocaine 0.05%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preinjecting lidocaine in a hand vein with a tourniquet
Number of subjects: 0
Study: 1375391

Group type: EXPERIMENTAL
Intervention: Self-expandable metal endoprosthesis
Number of subjects: 35
Study: 2865719

Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Thiopentone 4 mg/kg
Number of subjects: 60
Study: 30868692

Group type: EXPERIMENTAL
Intervention: Dementia Care Mapping (DCM)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Care-as-usual (CAU)
Number of subjects: 224
Study: 29481430

Group type: EXPERIMENTAL
Intervention: Midazolam and oxycodone
Number of subjects: 127

Group type: COMPARATOR
Intervention: Midazolam and sufentanil
Number of subjects: 127
Study: 27077832

Group type: EXPERIMENTAL
Intervention: 5% albumin solution between 8 and 12 hours post burn (n = 23)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group received 5% albumin solution 24 hours post burn (n = 23)
Number of subjects: 46
Study: 23015512

Group type: EXPERIMENTAL
Intervention: ER-fMRI
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Logistic regression using fMRI amplitude in right posterior cingulate and insular cortex
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Bayesian logistic regression and multilayer perceptron algorithms
Number of subjects: 45
Study: 22522549

Group type: EXPERIMENTAL
Intervention: BQ-123 (ETA receptor antagonist) at 400 nmol/minute for 60 minutes
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: BQ-123 (ETA receptor antagonist)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 20105313

Group type: EXPERIMENTAL
Intervention: Nursing home residents with stroke (n = 257)
Number of subjects: 3239
Study: 17827142

Group type: EXPERIMENTAL
Intervention: 3 day antibiotic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: 8 day antibiotic therapy
Number of subjects: 0
Study: 16210705

Group type: EXPERIMENTAL
Intervention: High vegetable and fruit diet (9.2 servings/d)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Low vegetable and fruit diet (3.6 servings/d)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Run-in diet (3.0 servings/d)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Switch from low to high vegetable and fruit diet
Number of subjects: 246
Study: 11172215

Group type: EXPERIMENTAL
Intervention: Sucralfate administered every 6 hours for 15 days (group A)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Water for injection with strawberry flavor as placebo (group B)
Number of subjects: 28
Study: 9512231

Group type: EXPERIMENTAL
Intervention: Falloposcopic tuboplasty (FT)
Number of subjects: 50
Study: 7748920

Group type: EXPERIMENTAL
Intervention: i.n. sCT 200 U/day
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: i.m. sCT 100 U/day
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 3173616

Group type: EXPERIMENTAL
Intervention: CA.RP (keto-analogs with low protein diet 0.4 g/kg/day)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CA.RN (keto-analogs with normal protein diet 1 g/kg/day)
Number of subjects: 15
Study: 31157963

Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg twice daily)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 154
Study: 28515063

Group type: EXPERIMENTAL
Intervention: Vegetable juices (beet, celery, and carrot) for 1 month starting at 0.5 months postpartum
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Vegetable juices (beet, celery, and carrot) for 3 months starting at 0.5 months postpartum
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (water)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Vegetable juices (beet, celery, and carrot)
Number of subjects: 97
Study: 25471002

Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiviral agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TENS and Antiviral agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 0
Study: 23458906

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy combined with parenting enhancement
Number of subjects: 226

Group type: COMPARATOR
Intervention: Equal attention-control condition
Number of subjects: 226
Study: 21673005

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg on alternate days
Number of subjects: 39757

Group type: COMPARATOR
Intervention: Control (no aspirin)
Number of subjects: 39757
Study: 18685525

Group type: EXPERIMENTAL
Intervention: Maltose (MAL)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Trehalose (TRE)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Water (WAT)
Number of subjects: 9
Study: 16492699

Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 21

Group type: COMPARATOR
Intervention: Snack (without or with acarbose)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Uncooked cornstarch
Number of subjects: 21

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 21
Study: 12612223

Group type: EXPERIMENTAL
Intervention: Intratracheal r‐h CuZnSOD (5 mg/kg in 2 mL/kg saline) every 48 hours for up to 1 month
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo every 48 hours for up to 1 month
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Intratracheal r‐h CuZnSOD (5 mg/kg in 2 mL/kg saline)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study: 10805052

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil/hydrochlorothiazide 8/12.5 mg once daily
Number of subjects: 353

Group type: COMPARATOR
Intervention: Lisinopril/hydrochlorothiazide 10/12.5 mg once daily
Number of subjects: 353
Study: 8680285

Group type: EXPERIMENTAL
Intervention: Antegrade cold blood cardioplegia (Group I, n=52)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combined antegrade/retrograde cardioplegia via coronary sinus cannulation (Group II, n=68)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Both groups (Group I and Group II)
Number of subjects: 120
Study: 6441624

Group type: EXPERIMENTAL
Intervention: Estrogen and calcium treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31754080

Group type: EXPERIMENTAL
Intervention: Mixed flavonoid supplementation (678 mg total, including 200 mg quercetin, 368 mg green tea catechins, 128 mg anthocyanins)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 29098555

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with cisplatin, etoposide, and irinotecan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topotecan alone
Number of subjects: 0
Study: 27136894

Group type: EXPERIMENTAL
Intervention: Internet-based peer-support group
Number of subjects: 124

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 124
Study: 24308676

Group type: EXPERIMENTAL
Intervention: Beta-alanine (BA) supplementation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 30
Study: 22697628

Group type: EXPERIMENTAL
Intervention: Collagen membrane (CM)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Expanded polytetrafluoroethylene (e-PTFE) membrane
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (implants surrounded by bone, no GBR)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study: 21271025

Group type: EXPERIMENTAL
Intervention: Conventional bevel-up tip position (GI)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Bevel-down tip position (GII)
Number of subjects: 25
Study: 17962331

Group type: EXPERIMENTAL
Intervention: Heat stress
Number of subjects: 17
Study: 15823832

Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized clinical trials
Number of subjects: 0
Study: 12660500

Group type: EXPERIMENTAL
Intervention: Rapamycin 2 mg/day
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (no rapamycin)
Number of subjects: 31
Study: 10589950

Group type: EXPERIMENTAL
Intervention: Sirolimus (1 or 3 mg/m2/day) with full‐dose CsA
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Sirolimus (1, 3, or 5 mg/m2/day) with reduced‐dose CsA
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group (placebo with full‐dose CsA)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Sirolimus (3 mg/m2/day) with full‐dose CsA
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Sirolimus with CsA and steroids
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Sirolimus with CsA
Number of subjects: 149
Study: 8929747

Group type: EXPERIMENTAL
Intervention: Diltiazem 30 mg 3 times daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Warfarin 25 mg oral dose
Number of subjects: 20
Study: 1926311

Group type: EXPERIMENTAL
Intervention: Regular blood donation by elderly
Number of subjects: 244
Study: 6355792

Group type: EXPERIMENTAL
Intervention: Cimetidine (1.0 g/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 6732224

Group type: EXPERIMENTAL
Intervention: Topical 10% acyclovir in polyethylene glycol ointment
Number of subjects: 352

Group type: COMPARATOR
Intervention: Polyethylene glycol alone (control)
Number of subjects: 352
Study: 30563118

Group type: EXPERIMENTAL
Intervention: Eyeglasses promotion program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eyeglasses promotion program (subgroup analysis)
Number of subjects: 0
Study: 26649651

Group type: EXPERIMENTAL
Intervention: Biolimus A9-eluting stent (BES)
Number of subjects: 1707

Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 1707
Study: 24394383

Group type: EXPERIMENTAL
Intervention: Quetiapine XR 50 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quetiapine XR 150 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quetiapine XR 300 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22706937

Group type: EXPERIMENTAL
Intervention: Sleeve brace
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Rigid shell brace
Number of subjects: 28

Group type: COMPARATOR
Intervention: Non-braced condition
Number of subjects: 28
Study: 21235040

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (up to 10 sessions, average of 8.6 sessions per patient)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 133
Study: 18524684

Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/d
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Pregabalin 450 mg/d
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg/d
Number of subjects: 750

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 750
Study: 15845676

Group type: EXPERIMENTAL
Intervention: Intraoperative music
Number of subjects: 80

Group type: COMPARATOR
Intervention: White noise
Number of subjects: 80

Group type: COMPARATOR
Intervention: Operating room noise
Number of subjects: 80
Study: 12588269

Group type: EXPERIMENTAL
Intervention: Bivalirudin with provisional Gp IIb/IIIa inhibition (n = 2999)
Number of subjects: 6010

Group type: COMPARATOR
Intervention: Heparin plus planned Gp IIb/IIIa inhibition (n = 3011)
Number of subjects: 6010

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 6010

Group type: COMPARATOR
Intervention: Heparin plus planned Gp IIb/IIIa inhibition
Number of subjects: 6010
Study: 10534851

Group type: EXPERIMENTAL
Intervention: Dynamic ultrasound images transmitted at 384 kbit/s
Number of subjects: 200

Group type: COMPARATOR
Intervention: Dynamic ultrasound images transmitted at 128 kbit/s
Number of subjects: 200
Study: 9546934

Group type: EXPERIMENTAL
Intervention: Heparin administration via nomogram (Group I)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Standard dosing scheme (Group II)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Standard dosing scheme (Group III)
Number of subjects: 161
Study: 1866869

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg p.o.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gentamicin 1.5 mg/kg IV
Number of subjects: 0
Study: 6337697

Group type: COMPARATOR
Intervention: DES 1 mg orally three times daily or orchiectomy
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: DES plus cyclophosphamide at 1 mg/m2 iv every three weeks
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Estracyt plus cyclophosphamide at 1 g/m2 iv every three weeks
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Chemotherapy (DES plus cyclophosphamide or Estracyt plus cyclophosphamide)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Hormone therapy alone
Number of subjects: 246
Study: 30825673

Group type: EXPERIMENTAL
Intervention: 0 wedges
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 3 wedges
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 5 wedges
Number of subjects: 12

Group type: COMPARATOR
Intervention: 0, 3, and 5 wedges
Number of subjects: 12
Study: 29045520

Group type: EXPERIMENTAL
Intervention: Cabozantinib (140 mg/day)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Cabozantinib (140 mg/day) in RET M918T-positive tumors
Number of subjects: 330

Group type: COMPARATOR
Intervention: Placebo in RET M918T-positive tumors
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Cabozantinib (140 mg/day) in RET M918T-negative tumors
Number of subjects: 330

Group type: COMPARATOR
Intervention: Placebo in RET M918T-negative tumors
Number of subjects: 330
Study: 25271811

Group type: EXPERIMENTAL
Intervention: Fixed-dose losartan 50 mg/hydrochlorothiazide 12.5 mg/amlodipine 5 mg (L50/H12.5/A5)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Losartan 50 mg/hydrochlorothiazide 12.5 mg (L50/H12.5)
Number of subjects: 0
Study: 24298783

Group type: EXPERIMENTAL
Intervention: Abdominal acupuncture with basic treatment (psychological counseling and Chinese patent medicine Rupixiao)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Routine treatment with basic treatment only
Number of subjects: 121
Study: 22292367

Group type: EXPERIMENTAL
Intervention: Kudiezi injection plus traditional Chinese medicine (TCM) synthesis rehabilitation project
Number of subjects: 700

Group type: COMPARATOR
Intervention: Synthetic rehabilitation project (Control)
Number of subjects: 700
Study: 19332202

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) and stenting with optimal medical therapy (1,101 patients)
Number of subjects: 2201

Group type: COMPARATOR
Intervention: Optimal medical therapy alone (1,100 patients)
Number of subjects: 2201

Group type: EXPERIMENTAL
Intervention: PCI in non-LAD group
Number of subjects: 2201

Group type: COMPARATOR
Intervention: Optimal medical therapy in non-LAD group
Number of subjects: 2201
Study: 16972811

Group type: EXPERIMENTAL
Intervention: Written emotional disclosure about stressful experiences
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control writing about neutral time management
Number of subjects: 83
Study: 15217075

Group type: EXPERIMENTAL
Intervention: Alcohol (n=18)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (n=7)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Time (n=8)
Number of subjects: 33
Study: 11424169

Group type: EXPERIMENTAL
Intervention: Placement of a depression health specialist in primary care practices
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced care arm (TAU with screening and assessment services)
Number of subjects: 0